NCT00005847 2023-06-22
Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Eastern Cooperative Oncology Group
Phase 2 Completed
Clinical Trials
14 trialsNCT00004124 2022-12-30
S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer
SWOG Cancer Research Network
Phase 3 Completed
NCT01204710 2019-09-20
A Study of Olaratumab (IMC-3G3) in Prostate Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00059631 2018-11-15
Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00331344 2017-10-31
Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00182741 2017-05-03
Calcitriol, Mitoxantrone, and Prednisone in Treating Patients With Metastatic Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Completed
NCT00017563 2017-04-28
Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Completed
NCT00058084 2017-02-23
Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00124566 2016-01-18
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Eisai Inc.
Phase 2 Completed
NCT00004001 2014-02-25
S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy
SWOG Cancer Research Network
Phase 3 Completed
NCT00004071 2012-09-11
Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer
Pfizer
Phase 2/3 Completed
NCT00003343 2012-08-08
Chemotherapy in Treating Patients Who Have Metastatic Prostate Cancer
Pfizer
Phase 3 Completed
NCT00436839 2012-07-09
Taxotere Prostate Cancer New Indication Registration Trial in China
Sanofi
Phase 3 Completed
NCT00627354 2011-05-16
Mitoxantrone, Etoposide, and Vinorelbine As Second-Line Therapy in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Completed